Inhibrx, Inc. (INBX)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

11025 N. TORREY PINES ROAD, SUITE 200 LA JOLLA, CA 92037

Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. Inhibrx has collaborations with bluebird bio, Bristol-Myers Squibb and Chiesi.

Data as of 2021-10-17 10:37:40 -0400
Market Cap1.505 Billion Shares Outstanding37.899 Million Avg 30-day Volume255.233 Thousand
P/E Ratio Dividend Yield EPS
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE-16.64 Enterprise Value
Total Cash Current Debt Gross Profit
BETA1.58169 52-week High/Low50.97 / 14.27 Next Earnings Date2021-11-08 Price to Cash FLow (P/CF) -66.8019
Data provided by IEX Cloud
View SEC Filings from INBX instead.

View recent insider trading info

Inhibrx, Inc. YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding INBX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding INBX BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

MANHARD KIMBERLY

  • Director
 35,759 2021-06-07 1

FORSYTH DOUGLAS

  • Director
 32,259 2021-06-07 1

KAYYEM JON FAIZ

  • Director
 32,259 2021-06-07 1

ECKELMAN BRENDAN P. CHIEF SCIENTIFIC OFFICER

ECKELMAN LIVING TRUST DATED FEBRUARY 5, 2014

  • Officer
  • Director
  • 10% Owner
 2,715,953 2021-03-24 3

WAGNER KLAUS W. CHIEF MEDICAL OFFICER

  • Officer
 215,150 2021-02-16 2

LAPPE MARK CHIEF EXECUTIVE OFFICER

LAPPE FAMILY TRUST

  • Officer
  • Director
  • TO BE VERIFIED
 3,149,714 2021-01-15 1

DECK KELLY CHIEF FINANCIAL OFFICER

  • Officer
 0 2021-01-15 1

VIKING GLOBAL INVESTORS LP

VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP

VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC

VIKING GLOBAL OPPORTUNITIES GP LLC

DRAGSA 50 LLC

HALVORSEN OLE ANDREAS

OTT DAVID C.

SHABET ROSE SHARON

  • 10% Owner
 5,305,866 2020-08-26 0

RA CAPITAL MANAGEMENT, L.P.

KOLCHINSKY PETER

SHAH RAJEEV M.

  • 10% Owner
 No longer subject to file 2020-08-21 0

KAYYEM JON FAIZ

JON F. KAYYEM & PAIGE GATES-KAYYEM FAMILY TRUST

  • Director
  • 10% Owner
 3,396,101 2020-08-18 1

DEVERAUX QUINN L.

  • 10% Owner
 2,749,953 2020-08-18 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
INHIBRX INC INBX 2021-10-21 19:15:02 UTC -0.7387 0.8087 100000
INHIBRX INC INBX 2021-10-21 18:45:03 UTC -0.8199 0.8899 100000
INHIBRX INC INBX 2021-10-21 18:15:03 UTC -0.8199 0.8899 100000
INHIBRX INC INBX 2021-10-21 17:45:03 UTC -0.8199 0.8899 100000
INHIBRX INC INBX 2021-10-21 17:15:03 UTC -0.8199 0.8899 100000
INHIBRX INC INBX 2021-10-21 16:45:03 UTC -0.8199 0.8899 100000
INHIBRX INC INBX 2021-10-21 16:15:03 UTC -0.8199 0.8899 100000
INHIBRX INC INBX 2021-10-21 15:45:03 UTC -0.8199 0.8899 100000
INHIBRX INC INBX 2021-10-21 15:15:03 UTC -0.8199 0.8899 100000
INHIBRX INC INBX 2021-10-21 14:45:03 UTC -0.7898 0.8598 100000
INHIBRX INC INBX 2021-10-21 14:15:03 UTC -0.7898 0.8598 100000
INHIBRX INC INBX 2021-10-21 13:45:03 UTC -0.7898 0.8598 100000
INHIBRX INC INBX 2021-10-21 13:15:02 UTC -0.7898 0.8598 100000
INHIBRX INC INBX 2021-10-21 12:45:03 UTC -0.7898 0.8598 100000
INHIBRX INC INBX 2021-10-20 22:15:03 UTC -0.7898 0.8598 100000
INHIBRX INC INBX 2021-10-20 21:45:03 UTC -0.7898 0.8598 100000
INHIBRX INC INBX 2021-10-20 21:15:03 UTC -0.7898 0.8598 100000
INHIBRX INC INBX 2021-10-20 20:45:03 UTC -0.7898 0.8598 100000
INHIBRX INC INBX 2021-10-20 20:15:03 UTC -0.7898 0.8598 100000
INHIBRX INC INBX 2021-10-20 19:45:04 UTC -0.7898 0.8598 100000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments